Stay updated on Magrolimab in Hematological Malignancies Clinical Trial
Sign up to get notified when there's something new on the Magrolimab in Hematological Malignancies Clinical Trial page.

Latest updates to the Magrolimab in Hematological Malignancies Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
- Check38 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check52 days agoChange DetectedThe latest update on January 17, 2025, includes the posting of results for various cohorts in a study involving magrolimab and azacitidine for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting new treatment protocols and participant eligibility criteria, while previous entries related to specific cohorts and treatment details have been removed.SummaryDifference100%
- Check59 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check89 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
Stay in the know with updates to Magrolimab in Hematological Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab in Hematological Malignancies Clinical Trial page.